My ePortfolio Register   

Lung cancer advances beyond PD1

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.07.17
Views: 593
Rating:

Dr Luis Raez - Medical Director, Memorial Cancer Institute, Miami, Florida, USA

Dr Raez speaks with ecancer at the Best of ASCO meeting in Miami about developments in immunotherapy for treating lung cancer initially presented at ASCO 2017.

Dr Raez last spoke with ecancer at ASCO 2017 to summarise these advances as they emerged.

He highlights the changing options in treating lung cancer over the last year, including approvals of pembrolizumab in advanced lung cancer for combinations and first line therapy, with trials for other checkpoint inhibitors ongoing.

Dr Raez also notes the impact of antibiotics on the lung microbiome impacting radiotherapy efficacy, emerging treatment options dependent on biomarker discoveries, and mechanisms of disease resistance.

 

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence